Last reviewed · How we verify
PRBC and cell saver Transfusion
PRBC and cell saver Transfusion, developed by The University of Texas Health Science Center, Houston, is a marketed product used in transfusion practices. A key strength is the protection of its core technology through a key composition patent expiring in 2028. The primary risk is the lack of clear revenue data and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | PRBC and cell saver Transfusion |
|---|---|
| Also known as | PRBC |
| Sponsor | The University of Texas Health Science Center, Houston |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Platelet Transfusion During Neonatal Open Heart Surgery (PHASE4)
- Use of Cell Salvage Post-operatively in Infants to Decrease Use of Allogeneic Blood Product Transfusions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: